A 28-year-old woman, gravida 1 para 0, at 39 weeks gestation is admitted to the labor and delivery unit for induction of labor due to gestational hypertension. An intravenous oxytocin infusion and a separate maintenance intravenous fluid infusion are initiated using adjacent electronic infusion pumps. Three hours later, the fetal heart rate monitor demonstrates recurrent late decelerations. The obstetrician immediately orders the oxytocin infusion to be discontinued. In the high-stress environment, the nurse mistakenly turns off the maintenance fluid pump instead of the oxytocin pump. Twenty minutes later, the patient develops prolonged uterine tachysystole, and the fetal heart rate drops to 60/min. The obstetrician returns to the room, identifies the pump programming error, and immediately stops the oxytocin. Despite intrauterine resuscitation, the fetal bradycardia persists, necessitating an emergent cesarean delivery. The neonate requires brief positive pressure ventilation but subsequently recovers well. Both mother and baby are currently stable. The physician openly discloses the medication error and subsequent sequence of events to the patient and her family. Which of the following is the most appropriate additional step for the hospital to take regarding this adverse event?
- Convene a multidisciplinary team to perform a root cause analysis to identify underlying latent system errorsCevap
- BInitiate a failure mode and effects analysis to retrospectively investigate the sequence of events
- CConclude the investigation by placing the involved nurse on administrative leave to reinforce accountability
- DOmit the medication error from the hospital's incident reporting system to protect staff from legal discovery
- ERequest a pharmacy consult to analyze potential pharmacokinetic interactions between oxytocin and the maintenance fluids